|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117405 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-23 11:10:44 |
|
注册时间: Date of Registration: |
2026-01-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
Mazor-X脊柱机器人辅助皮质骨轨迹螺钉治疗合并骨质疏松症的腰椎退变性疾病的前瞻性、随机对照研究 |
|
Public title: |
Mazor-X spinal robot-assisted cortical bone trajectory screw treatment for lumbar degenerative diseases combined with osteoporosis:A prospective, randomized controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
Mazor-X脊柱机器人辅助皮质骨轨迹螺钉治疗合并骨质疏松症的腰椎退变性疾病的前瞻性、随机对照研究 |
|
Scientific title: |
Mazor-X spinal robot-assisted cortical bone trajectory screw treatment for lumbar degenerative diseases combined with osteoporosis:A prospective, randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郭松 |
研究负责人: |
郭松 |
|
Applicant: |
Song Guo |
Study leader: |
Song Guo |
|
申请注册联系人电话: Applicant telephone: |
+86 178 2188 0206 |
研究负责人电话: Study leader's telephone: |
+86 1782180206 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
guosongtj@163.com |
研究负责人电子邮件: Study leader's E-mail: |
guosongtj@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市海宁路100号 |
研究负责人通讯地址: |
上海市海宁路100号 |
|
Applicant address: |
No. 100, Haining Road, Shanghai |
Study leader's address: |
No. 100, Haining Road, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
200080 |
研究负责人邮政编码: Study leader's postcode: |
200080 |
|
申请人所在单位: |
上海市第一人民医院 |
||
|
Applicant's institution: |
Shanghai First People's Hospital |
||
|
研究负责人所在单位: |
上海市第一人民医院 |
||
|
Affiliation of the Leader: |
Shanghai First People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
院伦审[2026]004号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第一人民医院人体试验伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee for Human Trials, Shanghai First People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-06 00:00:00 |
||
|
伦理委员会联系人: |
耿雯倩 |
||
|
Contact Name of the ethic committee: |
Wenqian Geng |
||
|
伦理委员会联系地址: |
上海市海宁路100号 |
||
|
Contact Address of the ethic committee: |
100 Haining Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 36126254 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai First People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市海宁路100号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
100 Haining Road, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市第一人民医院特色研究项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Clinical Research Innovation Plan of Shanghai General Hospital |
||||||||||||||||||||||
|
Target disease: |
Degenerative lumbar spine disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
观察Mazor-X脊柱机器人辅助CBT螺钉治疗合并骨质疏松症的腰椎退变性疾病的患者的有效性及安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of Mazor-X spinal robot-assisted CBT screw treatment in patients with lumbar degenerative diseases combined with osteoporosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)符合骨质疏松症诊断标准;骨质疏松症的诊断标准主要基于骨密度测定、脆性骨折史及临床风险因素的综合评估,具体如下:基于骨密度的诊断双能X线吸收法(DXA)是目前国际公认的诊断金标准。对于绝经后女性、50岁及以上男性,诊断标准如下:正常:T值>=-1.0;骨量减少:-2.5<T值<-1.0;骨质疏松:T值<=-2.5;严重骨质疏松:T值<=-2.5且伴有脆性骨折。对于儿童、绝经前女性和50岁以下男性,采用Z值评估,Z值<=-2.0提示骨密度低于同年龄段预期范围。基于脆性骨折的诊断:若存在髋部或椎体脆性骨折,无论骨密度如何,可直接诊断为骨质疏松症。若肱骨近端、骨盆或前臂远端发生脆性骨折,同时骨密度测量显示骨量减少(-2.5<T值<-1.0),也可诊断为骨质疏松症。 (2)保守治疗3月无效,包括物理治疗和非吗啡类药物治疗; (3)既往无其他脊柱手术史; (4)无其他重要脏器的功能障碍,能耐受手术。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Meets the diagnostic criteria for osteoporosis; The diagnostic criteria for osteoporosis are mainly based on the comprehensive assessment of bone density measurement, history of fragility fractures, and clinical risk factors. Specifically: Based on bone density, the dual-energy X-ray absorptiometry (DXA) is currently the internationally recognized gold standard for diagnosis. For postmenopausal women and men aged 50 and above, the diagnostic criteria are as follows: Normal: T value >= -1.0; Osteopenia: -2.5 < T value < -1.0; Osteoporosis: T value <= -2.5; Severe osteoporosis: T value <= -2.5 and accompanied by fragility fractures. For children, premenopausal women, and men under 50 years old, the Z value is used for assessment. A Z value <= -2.0 indicates that the bone density is below the expected range for the same age group. Based on fragility fractures: If there are fragility fractures in the hip or vertebrae, regardless of bone density, it can be directly diagnosed as osteoporosis. If fragility fractures occur in the proximal humerus, pelvis, or distal forearm, and bone density measurement shows bone loss (-2.5 < T value < -1.0), it can also be diagnosed as osteoporosis. (2) Conservative treatment for 3 months was ineffective, including physical therapy and non-opioid drug treatment; (3) There is no history of other spinal surgeries; (4) There are no other significant functional impairments of vital organs, and the patient can tolerate the surgery. |
||||||||||||||||||||||
|
排除标准: |
满足下列任一标准的研究参与者不具备入选本研究的资格: (1)严重凝血功能障碍性疾病或正口服抗凝药; (2)昏迷或无行为能力者; (3)MRI禁忌症(心脑血管等支架植入史、心脏起搏器、生物刺激器等); (4)严重感染未控制或高热者; (5)不能配合评估生活质量的患者。: |
||||||||||||||||||||||
|
Exclusion criteria: |
Research participants who meet any of the following criteria are not eligible for inclusion in this study: (1) Severe coagulation disorders or currently taking anticoagulant medication; (2) Comatose or unable to perform any actions; (3) MRI contraindications (history of cardiovascular or cerebrovascular stent implantation, cardiac pacemaker, biological stimulator, etc.); (4) Uncontrolled severe infection or high fever; (5) Patients unable to cooperate with quality of life assessments. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-07 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-23 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参与试验的研究者使用中央随机系统进行分层区组随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using a central randomization system, non-participating researchers conducted stratified block randomization. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲,对研究参与者和研究者设盲 |
|
Blinding: |
Double-blind, with both the research participants and the researchers being blinded. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |